AREG and pulmonary fibrosis: The identification of AREG as a key mediator in pulmonary fibrosis has prompted the development of targeted therapeutic strategies aimed at selectively inhibiting AREG signaling while avoiding the broad toxicities associated with general EGFR or TGF-β pathway inhibition.